Ceftaroline fosamil (Zinforo®) is recommended as an option for restricted use within NHS Wales. Ceftaroline fosamil (Zinforo®) should be restricted to use for the treatment of complicated skin and soft tissue infections in patients where methicillin-resistant S. aureus (MRSA) is suspected, only in the following settings:

• For infections caused by Gram-positive pathogens, only if intravenous (IV) vancomycin or IV teicoplanin is inappropriate, has not been tolerated or treatment modification is required; and IV daptomycin or IV linezolid is normally used.
• For mixed infections caused by common Gram-positive and Gram-negative pathogens (excluding extended-spectrum beta-lactamase-producing organisms, AmpC-producing organisms and non-fermenter Gram-negative organisms, such as Pseudomonas aeruginosa), only if IV vancomycin in combination with IV co-amoxiclav or IV teicoplanin in combination with IV co-amoxiclav is inappropriate, has not been tolerated or treatment modification is required; and IV daptomycin in combination with IV co-amoxiclav or IV linezolid in combination with IV co-amoxiclav is normally used.

Ceftaroline fosamil (Zinforo®) is not recommended for use within NHS Wales for the treatment of complicated skin and soft tissue infections outside of these settings. Ceftaroline fosamil (Zinforo®) is not recommended for use within NHS Wales for the treatment of community-acquired pneumonia.